Whitehawk (WHWK) Bryan Ball, Chief Technical Operations Officer, Receives Award

What Happened

• Bryan Ball, Chief Technical Operations Officer of Whitehawk Therapeutics (WHWK), was granted two derivative awards on September 15, 2026 — each for 91,633 shares, totaling 183,266 shares. Both grants are recorded at $0 (derivative awards/RSUs) and no cash changed hands. This filing is an amendment correcting vesting terms previously reported.

Key Details

• Transaction date: 2026-09-15; Amendment filed: 2026-09-18.
• Awards: two grants of 91,633 shares each (total 183,266); reported acquisition price $0.00 (derivative awards).
• Vesting:
  • One award: subject to a four-year vesting schedule — 25% vests on the one‑year anniversary of the Vesting Commencement Date, then 1/48th monthly thereafter (Vesting Commencement Date = Sept 15, 2026). (Footnote F1)
  • Other award: restricted stock units (RSUs); each RSU equals one share and, per the amended filing, will vest 100% on the one‑year anniversary of the Vesting Commencement Date (Sept 15, 2026). (Footnotes F2, F3)
• Shares owned after the transaction: not specified in the information provided.
• Filing notes: This is an amended Form 4 correcting an incorrect vesting schedule previously reported (see F3). The amended Form 4 was filed 3 days after the transaction date.

Context

• These are awards/RSUs (derivative grants) that are contingent on continued service; they do not represent open-market purchases or immediate sales. Vesting schedules determine when the underlying shares can be received. Because no shares were sold or bought on the open market, this is not a liquidity event and does not signal an immediate change in ownership.